BCN-PEG1-Val-Cit-PABC-OH

Cat. No.: HY-130923: FAQs
Data Sheet Handling Instructions Technical Support

BCN-PEG1-Val-Cit-PABC-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). BCN-PEG1-Val-Cit-PABC-OH is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

For research use only. We do not sell to patients.

BCN-PEG1-Val-Cit-PABC-OH Chemical Structure

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All ADC Linker Isoform Specific Products:

View All Isoforms

Cleavable Linker Non-cleavable Linker Acid Cleavable Linker Disulfide Cleavable Linker Protease Cleavable Linker Glycosidase Cleavable Linker Phosphatase Cleavable Linker

Biological Activity
Purity & Documentation
References
Customer Review

Description

BCN-PEG1-Val-Cit-PABC-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)^[1]. BCN-PEG1-Val-Cit-PABC-OH is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

IC₅₀ & Target

Protease Cleavable Linker

Cleavable Linker

In Vitro

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

670.80

Formula

C₃₄H₅₀N₆O₈

SMILES

O=C(NCCOCCC(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=O)C(NC1=CC=C(CO)C=C1)=O)=O)=O)OCC2[C@]3([H])[C@@]2([H])CCC#CCC3

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337. [Content Brief]